{"status": "ok", "totalResults": 3, "articles": [{"source": {"id": "bloomberg", "name": "Bloomberg"}, "author": "Jan-Henrik Foerster, Harry Wilson, Irina Anghel", "title": "Barclays to Cut Hundreds of Jobs Across Trading, Investment Bank - Bloomberg", "description": "Barclays Plc is preparing to cut hundreds of jobs as soon as next week as the firm looks to trim costs amid quieter markets.", "url": "https://www.bloomberg.com/news/articles/2023-09-08/barclays-to-cut-hundreds-of-jobs-across-trading-investment-bank", "urlToImage": "https://assets.bwbx.io/images/users/iqjWHBFdfxIU/iguftrP5MQds/v1/1200x800.jpg", "publishedAt": "2023-09-08T17:01:46Z", "content": "Barclays Plc is preparing to cut hundreds of jobs as soon as next week as the firm looks to trim costs amid quieter markets. \r\nThe lender is planning to dismiss about 5% of client-facing staff in the\u2026 [+290 chars]"}, {"source": {"id": "financial-times", "name": "Financial Times"}, "author": "Ivan Levingston, George Hammond, Tabby Kinder, Leo Lewis", "title": "SoftBank's $50bn Arm IPO more than five times oversubscribed, bankers say - Financial Times", "description": "Some fund managers on US roadshow see red flags in small size of listing and large number of banks involved", "url": "https://www.ft.com/content/a4dc854b-cdf9-4c13-b973-f39b3fa917a4", "urlToImage": "https://www.ft.com/__origami/service/image/v2/images/raw/https%3A%2F%2Fd1e00ek4ebabms.cloudfront.net%2Fproduction%2F7c437a32-4139-4574-ae80-204b7df90809.jpg?source=next-opengraph&fit=scale-down&width=900", "publishedAt": "2023-09-08T16:43:19Z", "content": "SoftBanks $50bn flotation of Arm is more than five times oversubscribed, according to bankers pitching investors on the biggest initial public offering in nearly two years, as the UK-based chip desig\u2026 [+5378 chars]"}, {"source": {"id": "reuters", "name": "Reuters"}, "author": "Reuters", "title": "Lilly's diabetes drug gains backing of UK watchdog -Bloomberg News - Reuters", "description": "Eli Lilly's <a href=\"https://www.reuters.com/markets/companies/LLY.N\" target=\"_blank\">(LLY.N)</a> diabetes drug Mounjaro has gained the backing of Britain's healthcare cost-effectiveness watchdog, which said it would be a good option for patients with poorly \u2026", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/lillys-diabetes-drug-gains-backing-uk-watchdog-bloomberg-news-2023-09-08/", "urlToImage": "https://www.reuters.com/resizer/1ZmgZD1C5NptBvvfCEsA5an61Nk=/1200x628/smart/filters:quality(80)/cloudfront-us-east-2.images.arcpublishing.com/reuters/FAQTJ67KUNKL3H6NZ4DIJMOMOI.jpg", "publishedAt": "2023-09-08T01:58:00Z", "content": "Sept 8 (Reuters) - Eli Lilly's (LLY.N) diabetes drug Mounjaro has gained the backing of Britain's healthcare cost-effectiveness watchdog, which said it would be a good option for patients with poorly\u2026 [+1477 chars]"}]}